莫西沙星 (Ｂａｙ1 2 -80 3 9)是由拜耳公司研发的一种新型的氟喹诺酮类药物 ,并已经经过ＦＤＡ的批准在美国上市。莫西沙星具有良好的药物代谢动力学特性 ,每日 1次 ,口服 40 0ｍｇ即可使血浆和组织浓度持续高于大部分呼吸道致病菌的ＭＩＣ90 。同早期喹诺酮类药物一样 ,莫西 Moxifloxacin (Bay1 2 -80 3 9) is a new fluoroquinolone drug developed by Bayer and is FDA-approved for marketing in the United States. Moxifloxacin has good pharmacokinetic properties, once daily, oral 40 0mg can make plasma and tissue concentrations continued to be higher than most of the respiratory pathogens MIC90. Like early quinolones, Moxi